Antidepressants for social anxiety disorder: A systematic review and meta‐analysis
Abstract Aim This systematic review is aimed to update and reintegrate the pharmacotherapy of social anxiety disorder (SAD), including the Japanese medical database. Methods We conducted a systematic review and meta‐analysis of pharmacotherapy of SAD according to the Medical Information Distribution...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-12-01
|
| Series: | Neuropsychopharmacology Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/npr2.12275 |
| _version_ | 1797979249565499392 |
|---|---|
| author | Nobuyuki Mitsui Yutaka Fujii Satoshi Asakura Hissei Imai Hisashi Yamada Naoki Yoshinaga Yoshihiro Kanai Takeshi Inoue Eiji Shimizu |
| author_facet | Nobuyuki Mitsui Yutaka Fujii Satoshi Asakura Hissei Imai Hisashi Yamada Naoki Yoshinaga Yoshihiro Kanai Takeshi Inoue Eiji Shimizu |
| author_sort | Nobuyuki Mitsui |
| collection | DOAJ |
| description | Abstract Aim This systematic review is aimed to update and reintegrate the pharmacotherapy of social anxiety disorder (SAD), including the Japanese medical database. Methods We conducted a systematic review and meta‐analysis of pharmacotherapy of SAD according to the Medical Information Distribution Service. We used data from a most recent systematic review, and updated search were conducted using MEDLINE, PubMed, CENTRAL, ICTRP, and ICHUSHI from August 1st, 2017 to January 31st, 2022. The outcome were response rates assessed by Clinical Global Impressions Improvement, efficacy assessed by the Liebowitz Social Anxiety Scale (LSAS), and dropout rates. We performed a random effect of meta‐analysis to obtain the differences in each outcome between active medication and placebo. We used RevMan version 5.3 for analyses. Results We identified 5 studies through update search and performed meta‐analysis for 33 studies on selective serotonin reuptake inhibitor (SSRI) and 6 studies on serotonin noradrenalin reuptake inhibitor (SNRI). The response rate (RR = 1.62) and the LSAS score reduction (mean difference = −9.65) of SSRI, and the response rate (RR = 1.57) and the LSAS score reduction (mean difference = −11.72) of SNRI were significantly different from placebo. The dropout rates of SSRI or SNRI were not significant. The response rates of SSRIs in both Japanese studies (RR = 1.44) and countries other than Japan (RR = 1.67) were significant. Most findings were based on low quality of evidence. Conclusion SSRIs are valid option for pharmacotherapy of SAD including Japanese patients. SNRIs are another effective option. However, the results should be interpreted cautiously due to several risk of bias. |
| first_indexed | 2024-04-11T05:35:57Z |
| format | Article |
| id | doaj.art-87c88ec8533b4783961751356af0b729 |
| institution | Directory Open Access Journal |
| issn | 2574-173X |
| language | English |
| last_indexed | 2024-04-11T05:35:57Z |
| publishDate | 2022-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neuropsychopharmacology Reports |
| spelling | doaj.art-87c88ec8533b4783961751356af0b7292022-12-22T12:22:50ZengWileyNeuropsychopharmacology Reports2574-173X2022-12-0142439840910.1002/npr2.12275Antidepressants for social anxiety disorder: A systematic review and meta‐analysisNobuyuki Mitsui0Yutaka Fujii1Satoshi Asakura2Hissei Imai3Hisashi Yamada4Naoki Yoshinaga5Yoshihiro Kanai6Takeshi Inoue7Eiji Shimizu8Department of Psychiatry Hokkaido University Graduate School of Medicine Sapporo JapanDepartment of Psychiatry Hokkaido University Graduate School of Medicine Sapporo JapanDepartment of Psychiatry Hokkaido University Graduate School of Medicine Sapporo JapanDepartment of Health Promotion and Human Behavior Kyoto University Graduate School of Medicine and School of Public Health Kyoto JapanDepartment of Neuropsychiatry Hyogo College of Medicine Hyogo JapanSchool of Nursing, Faculty of Medicine University of Miyazaki Miyazaki JapanDepartment of Human Science, Faculty of Liberal Arts Tohoku Gakuin University Sendai JapanDepartment of Psychiatry Tokyo Medical University Tokyo JapanCognitive Behavioral Therapy Center Chiba University Hospital Chiba JapanAbstract Aim This systematic review is aimed to update and reintegrate the pharmacotherapy of social anxiety disorder (SAD), including the Japanese medical database. Methods We conducted a systematic review and meta‐analysis of pharmacotherapy of SAD according to the Medical Information Distribution Service. We used data from a most recent systematic review, and updated search were conducted using MEDLINE, PubMed, CENTRAL, ICTRP, and ICHUSHI from August 1st, 2017 to January 31st, 2022. The outcome were response rates assessed by Clinical Global Impressions Improvement, efficacy assessed by the Liebowitz Social Anxiety Scale (LSAS), and dropout rates. We performed a random effect of meta‐analysis to obtain the differences in each outcome between active medication and placebo. We used RevMan version 5.3 for analyses. Results We identified 5 studies through update search and performed meta‐analysis for 33 studies on selective serotonin reuptake inhibitor (SSRI) and 6 studies on serotonin noradrenalin reuptake inhibitor (SNRI). The response rate (RR = 1.62) and the LSAS score reduction (mean difference = −9.65) of SSRI, and the response rate (RR = 1.57) and the LSAS score reduction (mean difference = −11.72) of SNRI were significantly different from placebo. The dropout rates of SSRI or SNRI were not significant. The response rates of SSRIs in both Japanese studies (RR = 1.44) and countries other than Japan (RR = 1.67) were significant. Most findings were based on low quality of evidence. Conclusion SSRIs are valid option for pharmacotherapy of SAD including Japanese patients. SNRIs are another effective option. However, the results should be interpreted cautiously due to several risk of bias.https://doi.org/10.1002/npr2.12275antidepressantsJapanmeta‐analysissocial anxiety disordersystematic review |
| spellingShingle | Nobuyuki Mitsui Yutaka Fujii Satoshi Asakura Hissei Imai Hisashi Yamada Naoki Yoshinaga Yoshihiro Kanai Takeshi Inoue Eiji Shimizu Antidepressants for social anxiety disorder: A systematic review and meta‐analysis Neuropsychopharmacology Reports antidepressants Japan meta‐analysis social anxiety disorder systematic review |
| title | Antidepressants for social anxiety disorder: A systematic review and meta‐analysis |
| title_full | Antidepressants for social anxiety disorder: A systematic review and meta‐analysis |
| title_fullStr | Antidepressants for social anxiety disorder: A systematic review and meta‐analysis |
| title_full_unstemmed | Antidepressants for social anxiety disorder: A systematic review and meta‐analysis |
| title_short | Antidepressants for social anxiety disorder: A systematic review and meta‐analysis |
| title_sort | antidepressants for social anxiety disorder a systematic review and meta analysis |
| topic | antidepressants Japan meta‐analysis social anxiety disorder systematic review |
| url | https://doi.org/10.1002/npr2.12275 |
| work_keys_str_mv | AT nobuyukimitsui antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT yutakafujii antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT satoshiasakura antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT hisseiimai antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT hisashiyamada antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT naokiyoshinaga antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT yoshihirokanai antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT takeshiinoue antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis AT eijishimizu antidepressantsforsocialanxietydisorderasystematicreviewandmetaanalysis |